India initiates probe against alleged dumping of Vitamin C from China
   Date :08-Sep-2020

Vitamin C _1  H
 
 
 
NEW DELHI :
 
INDIA has initiated a probe into the alleged dumping of Vitamin C, used by pharmaceutical firms for the production of medicines, from China following complaint by a domestic manufacturer. Bajaj Healthcare Ltd has filed the application before the Commerce Ministry’s investigation arm DGTR, seeking initiation of the probe.
 
The company alleged that the domestic industry is impacted due to the dumping of Vitamin C from China PR and has requested for the imposition of anti-dumping duty on the imports, according to the notification of Directorate General of Trade Remedies (DGTR). On the basis of prima facie evidence submitted by the applicants, “the authority, hereby, initiates an investigation,” it said.
 
In the probe, the directorate will determine the existence, degree and effect of any alleged dumping in respect of the product from China. If DGTR will find that there is dumping and it is impacting the domestic manufacturer, it will recommend the amount of anti-dumping duty, which if levied, would be adequate to remove the injury to the domestic industry. While the DGTR recommends the duty, the finance ministry imposes the same. The period of investigation is April 2019- March 2020. It would also look into the data of April 2016-19 period.